Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/37633
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLow M.S.Y.en
dc.contributor.authorBrodie E.J.en
dc.contributor.authorTarlinton D.M.en
dc.contributor.authorInfantino S.en
dc.date.accessioned2021-05-14T12:48:35Zen
dc.date.available2021-05-14T12:48:35Zen
dc.date.copyright2018en
dc.date.created20180313en
dc.date.issued2018-03-13en
dc.identifier.citationFrontiers in Immunology. 9 (MAR) (no pagination), 2018. Article Number: 401. Date of Publication: 01 Mar 2018.en
dc.identifier.issn1664-3224 (electronic)en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/37633en
dc.description.abstractSystemic lupus erythematosus (SLE) is a progressive autoimmune disease characterized by increased sensitivity to self-antigens, auto-antibody production, and systemic inflammation. B cells have been implicated in disease progression and as such represent an attractive therapeutic target. Lyn is a Src family tyrosine kinase that plays a major role in regulating signaling pathways within B cells as well as other hematopoietic cells. Its role in initiating negative signaling cascades is especially critical as exemplified by Lyn-/- mice developing an SLE-like disease with plasma cell hyperplasia, underscoring the importance of tightly regulating signaling within B cells. This review highlights recent advances in our understanding of the function of the Src family tyrosine kinase Lyn in B lymphocytes and its contribution to positive and negative signaling pathways that are dysregulated in autoimmunity.Copyright © 2018 Brodie, Infantino, Low and Tarlinton.en
dc.languageEnglishen
dc.languageenen
dc.publisherFrontiers Media S.A. (E-mail: info@frontiersin.org)en
dc.relation.ispartofFrontiers in Immunologyen
dc.titleLyn, lupus, and (B) lymphocytes, a lesson on the critical balance of kinase signaling in immunity.en
dc.typeReviewen
dc.type.studyortrialReview article (e.g. literature review, narrative review)-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.3389/fimmu.2018.00401en
dc.publisher.placeSwitzerlanden
dc.identifier.source620914679en
dc.identifier.institution(Brodie, Infantino, Low, Tarlinton) Department of Immunology and Pathology, Monash University, Melbourne, VIC, Australia (Low) Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia (Low) Immunology Division, Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Parkville, VIC, Australia (Low) Department of Haematology, Monash Health, Monash Hospital, Clayton, VIC, Australiaen
dc.description.addressD.M. Tarlinton, Department of Immunology and Pathology, Monash University, Melbourne, VIC, Australia. E-mail: david.tarlinton@monash.eduen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2018 Elsevier B.V., All rights reserved.en
dc.subect.keywordsAutoimmunity B cell B-cell receptor Cell signaling Lupus Lyn SFK Systemic lupus erythematosusen
dc.identifier.authoremailTarlinton D.M.; david.tarlinton@monash.eduen
dc.description.grantOrganization: (NHMRC) *National Health and Medical Research Council* Organization No: 501100000925 Country: Australiaen
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeReview-
Appears in Collections:Articles
Show simple item record

Page view(s)

4
checked on Sep 11, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.